Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes

Gene Therapy

Volumn 10, Issue 7, 2003, Pages 594-604

  Nguyen, P ^a   Geiger, T L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

CTL; Cytotoxicity; T cell receptor; Tolerance

Indexed keywords

CD28 ANTIGEN; CD8 ANTIGEN; CHIMERIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; CYTOLYSIS; DNA MODIFICATION; FEASIBILITY STUDY; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL;

ANIMALS; ANTIGENS, CD8; AUTOIMMUNE DISEASES; CD8-POSITIVE T-LYMPHOCYTES; GENE THERAPY; GREEN FLUORESCENT PROTEINS; H-2 ANTIGENS; IMMUNE TOLERANCE; LUMINESCENT PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037383920     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301932     Document Type: Article

References (37)

1. Wraith D et al. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell 1989; 59: 247-255.
2. Brocke S et al. Treatment of experimental autoimmume encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379: 343-346.
3. Legge KL et al. Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J Exp Med 2000; 191: 2039-2052.
4. Fink PJ, Shimonkevtz RP, Bevan MJ. Veto cells. Ann Rev Immunol 1988; 6: 115-137.
5. Reich-Zeliger S et al. Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 2000; 13: 507-515.
6. Geiger TL, Jyothi MD. Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus Med Rev 2001; 15: 21-34.
7. Mitsuyasu RT et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-793.
8. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157: 217-222.
9. Dazzi E, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477-1486.
10. Brodie SJ et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000; 105: 1407-1417.
11. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997; 45: 131-136.
12. Wels W et al. Biotechnological and gene therapeutic strategies in cancer treatment. Gene 1995; 159: 73-80.
13. Maher J et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20: 70-75.
14. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001; 98: 2364-2371.
15. Liu H, Rhodes M, Wiest DL, Vignali DA. On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 2000; 13: 665-675.
16. Huang JF et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 1999; 286: 952-954.
17. Raftery MJ et al. Herpes simplex virus type 1 infection of activated cytotoxic T cells: induction of fratricide as a mechanism of viral immune evasion. J Exp Med 1999; 190: 1103-1114.
18. Moss DJ, Burrows SR, Baxter GD, Lavin MF. T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J Exp Med 1991; 173: 681-686.
19. Gorman K et al. Cloned cytotoxic T lymphocytes as target cells. II. Polarity of lysis revisited. J Immunol 1988; 141: 2211-2215.
20. Jiang SB, Ojcius DM, Persechini PM, Young JD. Resistance of cytolytic lymphocytes to perforin-mediated killing. Inhibition of perforin binding activity by surface membrane proteins. J Immunol 1990; 144: 998-1003.
21. Blakely A et al. Resistance of cloned cytotoxic T lymphocytes to cell-mediated cytotoxicity. J Exp Med 1987; 166: 1070-1083.
22. Ojcius DM et al. Cytoplasts from cytotoxic T lymphocytes are resistant to perforin-mediated lysis. Mol Immunol 1991; 28: 1011-1018.
23. Verret CR, Firmenich AA, Kranz DM, Eisen HN. Resistance of cytotoxic T lymphocytes to the lytic effects of their toxic granules. J Exp Med 1987; 166: 1536-1547.
24. Bergenthal A, Hofmann M, Heeg K. Self-veto mechanism of CD8+ cytotoxic effector T cells. Peptide-induced paralysis affects the peptide-MHC-recognizing cytotoxic T lymphocytes and is independent of Fas/Fas ligand interactions. Eur J Immunol 1998; 28: 1911-1922.
25. Dutton R. The regulation of the development of CD8 effector T cells. J Immunol 1996; 157: 4287-4292.
26. Fehse B et al. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant 2000; 25(Suppl 2): S39-S42.
27. Guinan EC et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704-1714.
28. Jensen MC, Nademanee A, Forman SJ, Raubitschek A. Phase I trial of cellular immunotherapy for B cell lymphoma utilizing engineered CD20-specific CD8+ cytolytic T lymphocyte clones. Blood 2000; 96: 804a(abstract).
29. Xu XN et al. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 2001; 14: 591-602.
30. Su MW, Walden PR, Eisen HN, Golan DE. Cognate peptide-induced destruction of CD8+ cytotoxic T lymphocytes is due to fratricide. J Immunol 1993; 151: 658-667.
31. Walden PR, Eisen HN. Cognate peptides induce self-destruction of CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci USA 1990; 87: 9015-9019.
32. Sun J et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802-27809.
33. Rowley DA, Stach RM. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol 1998; 10: 355-363.
34. Pardoux C et al. Functional interaction between TGF-beta and IL-12 in human primary allogeneic cytotoxicity and proliferative response. J Immunol 1997; 158: 136-143.
35. Persons DA et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 1997; 90: 1777-1786.
36. Geiger T, Gooding LR, Flavell RA. T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1992; 89: 2985-2989.
37. Ausubel FM et al. Current Protocols in Molecular Biology. John Wiley and Sons: New York; 1989.